Last reviewed · How we verify
Inactivated HAV Vaccine, TZ84 Strain
The Inactivated HAV Vaccine, TZ84 Strain, developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, is a marketed vaccine for hepatitis A. The key composition patent expires in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Inactivated HAV Vaccine, TZ84 Strain |
|---|---|
| Also known as | Hepatitis A Vaccine, Inactivated |
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (PHASE3)
- The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (PHASE4)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: